Investing

Investing Idea - Dividend Growth

  • Last Updated:
  • May 24th, 2017 10:51 pm
Tags:
None
Member
Nov 1, 2010
389 posts
50 upvotes
Hello Rod,

Do you factor in exchange rates when making purchases?

Thx
Member
User avatar
Aug 13, 2004
337 posts
16 upvotes
Toronto
123nicolas wrote:
May 13th, 2017 12:13 pm
Hello Rod,

Do you factor in exchange rates when making purchases?

Thx
rodbarc wrote:
Apr 9th, 2017 1:39 am
No, I have zero consideration to what the FX gain might be. My US stocks are in RRSP only, so they are not subject to withhold taxes (and I get a bit of diversification, since I'm heavily invested in Canadian stocks on my taxable account). I contribute to my RRSP at every paycheque and reinvest the dividends where I find appropriate. Therefore, I dollar-cost-average the conversion to US (which is done only once, dividends settle in US$ and I do further conversion until withdraw times come). I see the current premium on potential currency depreciation as the cost to be exposed to good companies, that has a longer record of resilience regarding dividend growth, and which belongs to a stronger economy .

My setup is US dividend growth stocks (investing) in RRSP + Canadian dividend growth stocks (investing) in taxable account + US and Canadian stocks for trading (dividend and non-dividend) in TFSA.


Rod
see post #1675
investing-idea-dividend-growth-1587815/112/#p27665203


If you're going to to any USD CAD conversions in large amounts, I recommend you google "Norberts Gambit"
[OP]
Deal Addict
User avatar
Dec 14, 2010
4010 posts
2862 upvotes
jw513 wrote:
May 3rd, 2017 12:49 pm
Any thoughts on waste connections? WCN

Very small dividend but has raised it for 7 years straight, ever since they started
This never made it on my radar, probably because the ticker got renamed after they acquired BIN. At a glance it seems a good quality company. I will do more research and post my thoughts.


Rod
Newbie
May 18, 2017
4 posts
Have you ever looked at New Flyer Industries? They have grown significantly the past 2 years. After acquiring Motor coach industries, they have become the largest bus manufacturer in North America. Most of its sales come from the US as well. The low CAD has certainly been helping with its profits. Any thoughts?
[OP]
Deal Addict
User avatar
Dec 14, 2010
4010 posts
2862 upvotes
May 2017 purchases

May is always a nice month for me as I get extra cash from tax return to be invested.

Considering the existing live portfolio, and the goal to have a balanced sector distribution, I added the following companies last Friday:

Canadian portfolio: I took advantage of the recent bank decline and focused most on that sector. I`ve added EQB, IAG, IFC, LB and NA.

Image


Image


Image


Image


Image


US portfolio: I've added companies to populate other sectors that were not in the portfolio before. The criteria to pick a company was based on value and reasonable estimated growth. I've added INTC, GWW and AMP.


Image


Image


Image


Canadian portfolio updated:

Image
Image


Image



Rod
[OP]
Deal Addict
User avatar
Dec 14, 2010
4010 posts
2862 upvotes
babu928 wrote:
May 6th, 2017 12:59 am
Hi Rod,

I am wondering what you think about CVS and TEVA?
They are both trading far from 52 week highs and seems interesting as they are giants in their respective fields.

(I added 100 shares of CVS @ 80.86 as I have no exposure to the healthcare sector right now)
Historic P/E for CVS seems to be around 20, and it is at 16.xx right now... has grown its dividend for 10 years in a row...

Thank you for your valuable insight to this forum!
I didn't look into these specific companies, besides the fact that CVS has better estimates and prospects than TEVA. The whole industry has been affected lately and the pressure should continue until next year. I've gathered the following from S&P Global research, which might help to understand why price might remain disconnected from fundamentals for sometime, and like the energy sector a few years ago, this might present an entry opportunity to acquire quality companies.

"Our fundamental outlook for the pharmaceuticals sub-industry for the next 12 months is positive. Top-line pressure from patent expirations on many top-selling drugs bottomed in 2015 and we anticipate a modest sales increase of 5.2% in both 2016 and in 2017. We see a smaller adverse impact from foreign exchange in 2016 compared to 2015, but believe the firming of the U.S. dollar in late 2016 may lead to a more negative impact in 2017. We also see expanding sales of new innovative drug therapies and margin improvements accruing from cost restructurings and merger synergies. EPS comparisons should also benefit from common share repurchases.

While we see the Affordable Care Act (ACA) continuing to negatively affect industry margins, we see benefits, including improved sales demand, from the significant expansion of the insured population. According to the Department of Health and Human Services, approximately 22 million people obtained insurance since the law was enacted in 2010. However, with the Presidential election of Donald Trump and the Republicans retaining control of Congress, we are uncertain if the ACA or components of it will survive, particularly the Individual Mandate and the Medicaid expansion. Republicans have repeatedly threatened to repeal and replace the ACA, but have yet to propose concrete replacement plans.

Despite adverse effects from patent expirations and regulatory pressures on high drug pricing, we still think long-term prospects for the industry remain favorable. Pharmaceuticals remains one of the widest-margin U.S. industries, with prospects enhanced by demographic growth in the elderly (which account for about 33% of industry sales) and new drug discoveries. FDA approval of new molecular entities in 2015 rose to a robust 45 approvals, the most since 1996 when a record 53 were approved. This follows robust approvals in 2014 when 41 were approved (up from 27 in 2013 and 39 in 2012).

We expect prospects for the generic/specialty drug group to remain favorable as a large number of major drugs lost patent protection over the past few years, providing significant opportunities for this group. We favor companies with rich generic pipelines, especially those with first-to-file generics with the potential for 180 days of marketing exclusivity, and competence in litigating complex patent issues. But we note ongoing price pressure for generic drugs. In 2015, the S&P Pharmaceuticals Index rose 3.7%, versus a 1.0% decline in the &P 1500 Composite Index. Year-to-date through December 9, 2016 the S&P Pharmaceutical Index declined 6.5% vs. an 11.8% rise in the S&P 1500 Composite Index. "


Rod
Newbie
Feb 26, 2017
84 posts
19 upvotes
rodbarc wrote:
May 21st, 2017 11:44 am
I didn't look into these specific companies, besides the fact that CVS has better estimates and prospects than TEVA. The whole industry has been affected lately and the pressure should continue until next year. I've gathered the following from S&P Global research, which might help to understand why price might remain disconnected from fundamentals for sometime, and like the energy sector a few years ago, this might present an entry opportunity to acquire quality companies.

"Our fundamental outlook for the pharmaceuticals sub-industry for the next 12 months is positive. Top-line pressure from patent expirations on many top-selling drugs bottomed in 2015 and we anticipate a modest sales increase of 5.2% in both 2016 and in 2017. We see a smaller adverse impact from foreign exchange in 2016 compared to 2015, but believe the firming of the U.S. dollar in late 2016 may lead to a more negative impact in 2017. We also see expanding sales of new innovative drug therapies and margin improvements accruing from cost restructurings and merger synergies. EPS comparisons should also benefit from common share repurchases.

While we see the Affordable Care Act (ACA) continuing to negatively affect industry margins, we see benefits, including improved sales demand, from the significant expansion of the insured population. According to the Department of Health and Human Services, approximately 22 million people obtained insurance since the law was enacted in 2010. However, with the Presidential election of Donald Trump and the Republicans retaining control of Congress, we are uncertain if the ACA or components of it will survive, particularly the Individual Mandate and the Medicaid expansion. Republicans have repeatedly threatened to repeal and replace the ACA, but have yet to propose concrete replacement plans.

Despite adverse effects from patent expirations and regulatory pressures on high drug pricing, we still think long-term prospects for the industry remain favorable. Pharmaceuticals remains one of the widest-margin U.S. industries, with prospects enhanced by demographic growth in the elderly (which account for about 33% of industry sales) and new drug discoveries. FDA approval of new molecular entities in 2015 rose to a robust 45 approvals, the most since 1996 when a record 53 were approved. This follows robust approvals in 2014 when 41 were approved (up from 27 in 2013 and 39 in 2012).

We expect prospects for the generic/specialty drug group to remain favorable as a large number of major drugs lost patent protection over the past few years, providing significant opportunities for this group. We favor companies with rich generic pipelines, especially those with first-to-file generics with the potential for 180 days of marketing exclusivity, and competence in litigating complex patent issues. But we note ongoing price pressure for generic drugs. In 2015, the S&P Pharmaceuticals Index rose 3.7%, versus a 1.0% decline in the &P 1500 Composite Index. Year-to-date through December 9, 2016 the S&P Pharmaceutical Index declined 6.5% vs. an 11.8% rise in the S&P 1500 Composite Index. "


Rod
One thing that drove down the share price this week was rumors that Amazon is going to enter the sector (both CVS and WBA were down about 5% this week).

https://www.bloomberg.com/gadfly/articl ... pharmacies

I bought a position for CVS in March and I'm hopeful it will be a good long term hold.
Member
Aug 17, 2008
442 posts
114 upvotes
FYI

"Dividend Growers vs High Dividend Yielders: How They Compared as Interest Rates Rose"

http://www.indexologyblog.com/2017/05/2 ... ates-rose/

There are generally two types of dividend strategies:

1 - Dividend growers: Those targeting stocks that consistently grow their dividends over time
2 - High dividend yielders: Those focusing on stocks that pay a high dividend yield

Not all dividend strategies are created equal

These dividend strategies are constructed differently and may be used to accomplish different objectives. For example, investors seeking a greater-than-average income may choose high dividend yield strategies. But these strategies tend to have significant weightings in sectors that are highly sensitive to interest rate movements, thus introducing interest rate risk into the equity allocation.

On the other hand, strategies focused on stocks that have grown their dividends consistently (but don’t always have the highest yields) may provide an all-weather dividend solution—one that has the potential to perform well regardless of the direction of rates.

Comparing dividend growers and high dividend yielders in different rate environments

Let’s examine two popular dividend indexes as an example: S&P 500® Dividend Aristocrats® Index (dividend growers) vs. Dow Jones U.S. Select DividendTM Index (high dividend yielders).

<see attachment>

For illustrative purposes only. Source: Bloomberg, 5/2/05–3/31/17. Results show average performance of dividend strategies based on monthly interest rate changes. S&P 500 Dividend Aristocrats measures the performance of S&P 500 companies that have increased dividends every year for the last 25 consecutive years. Dow Jones U.S. Select Dividend Index represents the United States’ leading stocks by dividend yield; this index is shown here because it is tracked by the largest high dividend yield ETF by assets. Past performance is not a guarantee of future results. There is no guarantee dividends will be paid. Companies may reduce or eliminate dividends at any time, and those that do will be dropped from the indexes at reconstitution.

The takeaway

As investors consider dividend strategies, it’s important to note the difference between high dividend yield strategies and dividend growth strategies. While the former may provide the higher income many investors crave, they tend to be sensitive to interest rate movements. The latter, on the other hand, offer all-weather potential, having performed well in a variety of interest rate environments.
Images
× < >
Rotate image Save Cancel

Top